Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 117, Issue 3, 2009, Pages 615-623

  Mayer, E L ^a   Partridge, A H ^a   Harris, L N ^b   Gelman, R S ^a   Schumer, S T ^a   Burstein, H J ^a   Winer, E P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Adherence; Breast cancer; Capecitabine; EGFR; Gefitinib; Metastatic; Phase 1

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREATITIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MAXIMUM TOLERATED DOSE; MEDICATION ADHERENCE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349565756     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0366-5     Document Type: Article

References (47)

1. JG Klijn PM Berns PI Schmitz JA Foekens 1992 The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5,232 patients Endocr Rev 13 3 17 1313356 1:STN:280:DyaK383gvFCnsQ%3D%3D
2. D Busse FM Yakes AE Lenferink CL Arteaga 2001 Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance Semin Oncol 28 47 55 10.1016/S0093-7754(01)90282-9 11706396 10.1016/S0093-7754(01) 90282-9 1:CAS:528:DC%2BD3MXpt1Wgu7g%3D
3. F Ciardiello R Caputo R Bianco, et al. 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 2053 2063 10815932 1:CAS:528:DC%2BD3cXktVWitrs%3D
4. SL Moulder FM Yakes SK Muthuswamy, et al. 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res 61 8887 8895 11751413 1:CAS:528:DC%2BD38Xht1Oltg%3D%3D
5. NG Anderson T Ahmad K Chan, et al. 2001 ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression Int J Cancer 94 774 782 10.1002/ijc.1557 11745477 10.1002/ijc.1557 1:CAS:528:DC%2BD3MXotFOkur8%3D (Pubitemid 33032823)
6. MM Moasser A Basso SD Averbuch N Rosen 2001 The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 61 7184 7188 11585753 1:CAS:528:DC%2BD3MXnsVehtrY%3D
7. RI Nicholson IR Hutcheson ME Harper, et al. 2001 Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer Endocr Relat Cancer 8 175 182 10.1677/erc.0.0080175 11566608 10.1677/erc.0.0080175 1:CAS:528:DC%2BD3MXotlCqsLo%3D (Pubitemid 32947639)
8. JM Knowlden IR Hutcheson HE Jones, et al. 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032 1044 10.1210/en.2002-220620 12586780 10.1210/en.2002-220620 1:CAS:528:DC%2BD3sXhslCqtro%3D (Pubitemid 36262870)
9. J Shou S Massarweh CK Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 935 15199112 1:CAS:528: DC%2BD2cXltVWmtLY%3D
10. C Lu C Speers Y Zhang, et al. 2003 Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors J Natl Cancer Inst 95 1825 1833 14679152 1:CAS:528:DC%2BD3sXhtVShsbrL
11. J Baselga D Rischin M Ranson, et al. 2002 Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 4292 4302 10.1200/JCO.2002.03.100 12409327 10.1200/JCO.2002.03.100 1:CAS:528:DC%2BD38Xpt1CjtLo%3D (Pubitemid 35266289)
12. RS Herbst AM Maddox ML Rothenberg, et al. 2002 Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 3815 3825 10.1200/JCO.2002.03.038 12228201 10.1200/JCO.2002.03.038 1:CAS:528: DC%2BD38XntVyns7s%3D (Pubitemid 35050835)
13. M Ranson LA Hammond D Ferry, et al. 2002 ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2240 2250 10.1200/JCO.2002.10.112 11980995 10.1200/JCO.2002.10. 112 1:CAS:528:DC%2BD38XktVKrsrc%3D (Pubitemid 34441651)
14. J Baselga J Albanell A Ruiz, et al. 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 5323 5333 10.1200/JCO.2005.08.326 15939921 10.1200/JCO.2005.08.326 1:CAS:528:DC%2BD2MXpslOrtLs%3D (Pubitemid 46206986)
15. KS Albain R Elledge WJ Gradishar, et al. 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer Breast Cancer Res 76 S33 A20
16. Robertson JFR, Gutteridge E, Cheung KL, et al (2003) Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. J Clin Oncol 22:A23. 2003 ASCO annual meeting proceedings (post-meeting edition)
17. G von Minckwitz W Jonat P Fasching, et al. 2005 A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 165 172 10.1007/s10549-004-1720-2 10.1007/s10549-004-1720-2 1:CAS:528:DC%2BD2MXhtVamsro%3D (Pubitemid 40249050)
18. JL Blum V Dieras PM Lo Russo, et al. 2001 Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A 11745247 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A 1:CAS:528:DC%2BD3MXosV2qsLw%3D (Pubitemid 32952493)
19. JL Blum SE Jones AU Buzdar, et al. 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493 10080589 1:CAS:528:DyaK1MXht1Wmurw%3D
20. DC Talbot V Moiseyenko S Van Belle, et al. 2002 Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 1367 1372 10.1038/sj.bjc.6600261 11986765 10.1038/sj.bjc.6600261 1:CAS:528:DC%2BD38XkvVKjsLo%3D (Pubitemid 34548055)
21. P Fumoleau R Largillier C Clippe, et al. 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542 10.1016/j.ejca.2003.11.007 14962720 10.1016/j.ejca.2003.11.007 1:CAS:528:DC%2BD2cXhtFWjsbc%3D (Pubitemid 38220770)
22. JA O'Shaughnessy J Blum V Moiseyenko, et al. 2001 Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 1247 1254 10.1023/A:1012281104865 10.1023/A:1012281104865 (Pubitemid 32994752)
23. N Magne JL Fischel A Dubreuil, et al. 2003 ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine Clin Cancer Res 9 4735 4742 14581344 1:CAS:528:DC%2BD3sXosVGjsL8%3D
24. KF Ouchi M Yanagisawa F Sekiguchi Y Tanaka 2006 Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models Cancer Chemother Pharmacol 57 693 702 10.1007/s00280-005-0079-3 16362295 10.1007/s00280-005-0079-3 1:CAS:528:DC%2BD28Xjs1KktLc%3D
25. DM Waterhouse KA Calzone C Mele DE Brenner 1993 Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring J Clin Oncol 11 1189 1197 8501505 1:STN:280:DyaK3s3nsVentQ%3D%3D
26. TA Traina M Theodoulou K Feigin, et al. 2008 Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer J Clin Oncol 26 1797 1802 10.1200/JCO.2007.13.8388 18398145 10.1200/JCO.2007.13.8388 1:CAS:528:DC%2BD1cXmsFemsLc%3D
27. G Gasparini R Sarmiento S Amici, et al. 2005 Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate Ann Oncol 16 1867 1873 10.1093/annonc/mdi393 16107496 10.1093/annonc/mdi393 1:STN:280:DC%2BD2MnisVOgtQ%3D%3D (Pubitemid 41724274)
28. G Fountzilas D Pectasides A Kalogera-Fountzila, et al. 2005 Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the hellenic cooperative oncology group Breast Cancer Res Treat 92 1 9 10.1007/s10549-005-0322-y 15980985 10.1007/s10549-005-0322-y 1:CAS:528:DC%2BD2MXls1Sms7w%3D (Pubitemid 40875072)
29. F Ciardiello T Troiani F Caputo, et al. 2006 Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer Br J Cancer 94 1604 1609 16685276 1:CAS:528:DC%2BD28XltVOmtLg%3D
30. SK Dennison SA Jacobs JW Wilson, et al. 2007 A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer Invest New Drugs 25 545 551 10.1007/s10637-007-9055-6 17563856 10.1007/s10637-007-9055-6 1:CAS:528:DC%2BD2sXhtFSlsbzM
31. M Cristofanilli V Valero A Mangalik, et al. 2008 A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) J Clin Oncol 26 A1012 10.1200/JCO.2008.18. 0356 10.1200/JCO.2008.18.0356
32. Winer E, Cobleigh M, Dickler M, et al (2002) Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76:A445. 2002 san antonio breast cancer symposium proceedings (post-meeting edition)
33. AR Tan X Yang SM Hewitt, et al. 2004 Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor J Clin Oncol 22 3080 3090 10.1200/JCO.2004.08.189 15284258 10.1200/JCO.2004.08.189 1:CAS:528:DC%2BD2cXpsVGrsr0%3D (Pubitemid 41103720)
34. G Giaccone RS Herbst C Manegold, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784 10.1200/JCO.2004.08.001 14990632 10.1200/JCO.2004.08.001 1:CAS:528:DC%2BD2cXpsVKjur4%3D (Pubitemid 41103588)
35. RS Herbst G Giaccone JH Schiller, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794 10.1200/JCO.2004.07.215 14990633 10.1200/JCO.2004.07.215 1:CAS:528:DC%2BD2cXpsVKjur0%3D (Pubitemid 41103589)
36. RS Herbst D Prager R Hermann, et al. 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899 10.1200/JCO.2005.02.840 16043829 10.1200/JCO.2005.02.840 1:CAS:528: DC%2BD2MXhtVKgtbzN (Pubitemid 46300205)
37. U Gatzemeier A Pluzanska A Szczesna, et al. 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545 1552 10.1200/JCO.2005.05.1474 17442998 10.1200/JCO.2005.05.1474 1:CAS:528:DC%2BD2sXlsVynur4%3D (Pubitemid 46733081)
38. Bailey LR, Janas M, Schmidt K, et al (2004) Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. J Clin Oncol 22:A7013. 2004 ASCO annual meeting proceedings (post-meeting edition)
39. A Polychronis HD Sinnett D Hadjiminas, et al. 2005 Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Lancet Oncol 6 383 391 10.1016/S1470-2045(05)70176-5 15925816 10.1016/S1470-2045(05)70176-5 1:CAS:528:DC%2BD2MXltFWktL0%3D (Pubitemid 40753744)
40. L Carey H Rugo P Marcom, et al. 2008 TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer J Clin Oncol 26 A1009
41. G Arpino L Wiechmann CK Osborne R Schiff 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217 233 10.1210/er.2006-0045 18216219 10.1210/er.2006-0045 1:CAS:528:DC%2BD1cXltlOhsrk%3D
42. AH Partridge J Avorn PS Wang EP Winer 2002 Adherence to therapy with oral antineoplastic agents J Natl Cancer Inst 94 652 661 11983753
43. L Atkins L Fallowfield 2006 Intentional and non-intentional non-adherence to medication amongst breast cancer patients Eur J Cancer 42 2271 2276 10.1016/j.ejca.2006.03.004 16644208 10.1016/j.ejca.2006.03.004 (Pubitemid 44307611)
44. AH Partridge A LaFountain E Mayer, et al. 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556 562 10.1200/JCO.2007.11.5451 18180462 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D (Pubitemid 351264348)
45. J Urquhart 1991 Compliance and clinical trials Lancet 337 1224 1225 10.1016/0140-6736(91)92896-A 1673762 10.1016/0140-6736(91)92896-A 1:STN:280:DyaK3M3hvVKjsA%3D%3D
46. Lasagna L, Hutt P (1991) Heath care, research and regulatory impact of noncompliance. In: Cramer JA, Spikler BE (eds) Patient compliance in medical practice and clinical trials. Raven Press, New York, pp 393-403 Edition
47. H Leventhal DR Nerenz EA Leventhal, et al. 1991 The behavioral dynamics of clinical trials Prev Med 20 132 146 10.1016/0091-7435(91)90014-U 2008422 10.1016/0091-7435(91)90014-U 1:STN:280:DyaK3M7otVSnsQ%3D%3D